Although reduction of LC3B in immune-refractory cancer models can render malignancies susceptible to pericyte metastasis and PD-1/PD-L1 inhibition, resulting in successful long-term control of tumors like colorectal cancer. This evidence concerns the gene MAP1LC3B and cancer.